What is Zacks Research's Forecast for Sanofi Q1 Earnings?

Sanofi (NASDAQ:SNY - Free Report) - Zacks Research dropped their Q1 2026 earnings per share estimates for Sanofi in a note issued to investors on Wednesday, February 19th. Zacks Research analyst K. Shah now anticipates that the company will post earnings per share of $1.05 for the quarter, down from their prior estimate of $1.06. The consensus estimate for Sanofi's current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi's Q4 2026 earnings at $1.19 EPS, FY2026 earnings at $4.75 EPS and FY2027 earnings at $5.16 EPS.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%.

A number of other brokerages have also recently issued reports on SNY. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Finally, StockNews.com cut Sanofi from a "buy" rating to a "hold" rating in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $60.00.

Sanofi Stock Up 2.1 %

NASDAQ SNY traded up $1.14 during trading hours on Friday, hitting $54.89. 2,763,445 shares of the company traded hands, compared to its average volume of 2,419,276. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The business's 50-day moving average is $51.10 and its 200-day moving average is $52.55. The stock has a market capitalization of $139.30 billion, a price-to-earnings ratio of 22.04, a P/E/G ratio of 1.01 and a beta of 0.57. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97.

Institutional Trading of Sanofi

A number of hedge funds have recently modified their holdings of SNY. Synergy Asset Management LLC bought a new position in Sanofi in the 4th quarter valued at about $25,000. Concord Wealth Partners increased its stake in shares of Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company's stock worth $34,000 after purchasing an additional 363 shares during the period. McClarren Financial Advisors Inc. lifted its holdings in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after purchasing an additional 543 shares during the last quarter. Bessemer Group Inc. lifted its holdings in Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after purchasing an additional 242 shares during the last quarter. Finally, Lee Danner & Bass Inc. bought a new stake in Sanofi in the 4th quarter valued at $31,000. Institutional investors and hedge funds own 14.04% of the company's stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.